Morepen Q2 FY27: revenue up 81% to Rs. 755 Cr, PAT up 117% as CDMO supplies scale up
Q2 FY27 revenue up 81% YoY to Rs. 755 Cr, EBITDA up 273% to Rs. 132 Cr, PAT up 117% to Rs. 89 Cr.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- Rs. 755 Cr (+81% YoY)
- Q2 FY27 EBITDA
- Rs. 132 Cr (+273%), margin 17.45% (+897 bps)
- Q2 FY27 PAT
- Rs. 89 Cr (+117%)
- Period
- Q2 & H1 FY27
- Positioning
- Morepen describes itself as a diversified, compliant and scalable API, CDMO and Devices platform exporting to over 90 countries, with exports about half of sales.
💰 Q2 FY27 revenue was Rs. 755 Cr (+81% YoY), EBITDA Rs. 132 Cr (+273%), margin 17.45% (+897 bps) and PAT Rs. 89 Cr (+117%). H1 revenue was Rs. 1330 Cr (+57%) with PAT Rs. 145 Cr (+177%). TTM ROCE rose to 18.8% from 9.4% in FY26, while debt/equity moved to 0.23x from 0.17x.
🌍 CDMO revenue rose from Rs. 58 Cr in Q1 to Rs. 253 Cr in Q2 (4.3x QoQ), reaching 52% of API + CDMO revenue. H1 exports were Rs. 654 Cr, up 122% YoY, taking exports to about 50% of sales versus 35% a year earlier.
🔬 Management states its transformation is from an API-led to an API+CDMO+Devices mix, with higher-quality earnings, higher operating leverage and longer-duration programmes. The company says new molecules are now 25% of API revenue, up from 14%.
🏭 The presentation lists capacity moving from 614 KL to 800 KL with further expansion behind visibility, plus an Innovation Hub and new technologies; the company says Q2 earnings strength enables the next phase of expansion, backed by a Rs. 825 Cr global CDMO mandate from Feb'26.
Also from Morepen Laboratories
Designations of two senior management personnel changed on promotion, effective 27th October 2026
27 Oct 2026
Monitoring agency flags capex delay risk on QIP proceeds; Rs. 1.12 crore spent in Q2FY27
27 Oct 2026
Morepen Q2 FY27: CDMO revenue Rs. 253 Cr, first capacity phase completed at 614 KL
27 Oct 2026
More numbers
- Revenue, Q2 FY27Rs. 755 Cr
- Revenue growth YoY, Q2 FY27+81%
- EBITDA, Q2 FY27Rs. 132 Cr
- EBITDA margin, Q2 FY2717.45%
- PAT, Q2 FY27Rs. 89 Cr
- Revenue, H1 FY27Rs. 1330 Cr
- PAT, H1 FY27Rs. 145 Cr
- ROCE, TTM18.8%
- CDMO revenue, Q2 FY27Rs. 253 Cr
- Export revenue, H1 FY27Rs. 654 Cr
- H1 CDMO revenueRs. 311 Cr
- Global CDMO mandate (Feb'26)Rs. 825 Cr
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.